Results 11 to 20 of about 6,309 (194)

Real‐world characteristics and treatment of cardiac transthyretin amyloidosis: A multicentre, observational study

ESC Heart Failure
Aims Data on the clinical profiles of patients with transthyretin amyloidosis cardiomyopathy (ATTR‐CM) in the post‐approval era of tafamidis 61 mg are lacking.
Richard J. Nies, Svenja Ney, Ingrid Kindermann, Yvonne Bewarder, Angela Zimmer, Fabian Knebel, Katrin Hahn, Sebastian Spethmann, Peter Luedike, Lars Michel, Tienush Rassaf, Maria Papathanasiou, Stefan Störk, Vladimir Cejka, Amin Polzin, Fabian Voss, Malte Kelm, Bernhard Unsöld, Christine Meindl, Michael Paulus, Ali Yilmaz, Bishwas Chamling, Caroline Morbach, Roman Pfister   +23 more
doaj   +2 more sources

Wild Type Transthyretin Amyloid Cardiomyopathy Hidden Under Ablation-Refractory Atrial Arrhythmias and the Potential Contribution of Tafamidis in Rhythm Control. [PDF]

J Arrhythm
An octogenarian man with a history of multiple catheter ablation failures for atrial fibrillation and tachycardia was diagnosed with transthyretin amyloid cardiomyopathy. After 1 year of tafamidis therapy, the patient experienced spontaneous restoration of sinus rhythm, and follow‐up image of 99mTc‐pyrophosphate scintigraphy revealed a marked decrease ...
Horie T, Nagata Y, Nozato T, Miyazaki S, Ashikaga T.   +4 more
europepmc   +2 more sources

Clinical phenotype and prognosis of real-world patients with wild-type transthyretin amyloid cardiomyopathy treated with tafamidis. [PDF]

Eur J Heart Fail
Aims Tafamidis reshaped the treatment paradigm in transthyretin amyloid cardiomyopathy (ATTR‐CM) based on a phase‐3 randomized controlled trial, but real‐world data on its use remain limited. This study aimed to assess in a large, contemporary, real‐world cohort of patients with wild‐type ATTR‐CM (ATTRwt‐CM) (i) the clinical phenotype of patients ...
Porcari A, Milani P, Longhi S, Cappelli F, Vagnarelli F, Aimo A, Cipriani A, Gardini E, Marazia S, Monda E, Tini G, Musumeci B, Serenelli M, Cantone A, Lofiego C, Marini M, Vergaro G, Foti G, Musca F, Tomasoni D, Bonacchi G, Colio F, Sinigiani G, De Michieli L, Sturdà F, Pozzan M, Gentile P, Carigi S, Bartolotti M, Sena G, Ruotolo I, Sanna GD, Zanoletti M, Canepa M, Di Marco M, D'Elia E, Di Bella G, Driussi M, Imazio M, Perfetto F, Biagini E, Limongelli G, Metra M, Emdin M, Merlini G, Perlini S, Merlo M, Palladini G, Sinagra G.   +48 more
europepmc   +2 more sources

Health-related quality of life in hereditary transthyretin amyloidosis polyneuropathy: a prospective, observational study [PDF]

, 2020
Background Hereditary Transthyretin Amyloidosis Polyneuropathy is a rare life-threatening neurologic disease that imposes considerable mortality and it is associated with progressive related disabilities.
Coelho, Teresa, Conceição, Isabel, Costa, João, de Carvalho, Mamede, Ferreira, Lara, Inês, Mónica   +5 more
core   +2 more sources

Tafamidis Drug Delivery Systems Based on Chitosan/Polyvinyl Alcohol Matrix

Engineering Proceedings, 2023
Cardiovascular diseases retain their position as the leading cause of death globally, and according to the World Health Organization, there are 17.9 million cases of these diseases each year.
Petr Snetkov, Yuliya Generalova, Thi Hong Nhung Vu, Svetlana Morozkina, Mayya Uspenskaya   +4 more
doaj   +1 more source

Tafamidis decreased cardiac amyloidosis deposition in patients with Ala97Ser hereditary transthyretin cardiomyopathy: a 12-month follow-up cohort study

Orphanet Journal of Rare Diseases, 2023
Background Transthyretin cardiac cardiomyopathy (ATTR-CM) is a rare but life-threatening disease. Tafamidis is an effective treatment for patients with ATTR-CM, however its long-term effects on cardiac remodeling and cardiac amyloid deposition are ...
Cheng-Hsuan Tsai, Chi-Chao Chao, Sung-Tsang Hsieh, An-Li Yu, Yuan-Kun (Aden) Wu, Mei-Fang Cheng, Ming-Jen Lee, Chia-Hung Chou, Chia-Tung Shun, Hsueh-Wen Hsueh, Jimmy Jyh-Ming Juang, Ping-Huei Tseng, Mao-Yuan Su, Yen-Hung Lin   +13 more
doaj   +1 more source

Thermal and Structural Characterization of Two Crystalline Polymorphs of Tafamidis Free Acid

Molecules, 2022
Tafamidis, chemical formula C14H7Cl2NO3, is a drug used to delay disease progression in adults suffering from transthyretin amyloidosis, and is marketed worldwide under different tradenames as a free acid or in the form of its meglumine salt.
Norberto Masciocchi, Vincenzo Mirco Abbinante, Marco Zambra, Giuseppe Barreca, Massimo Zampieri   +4 more
doaj   +1 more source

Uncovering the Mechanism of Aggregation of Human Transthyretin. [PDF]

, 2015
The tetrameric thyroxine transport protein transthyretin (TTR) forms amyloid fibrils upon dissociation and monomer unfolding. The aggregation of transthyretin has been reported as the cause of the life-threatening transthyretin amyloidosis.
Cascio, Duilio, Eisenberg, David S, Jiang, Lin, Johnson, Lisa M, Liang, Wilson Y, Riek, Roland, Ruchala, Piotr, Saelices, Lorena, Sawaya, Michael R, Whitelegge, Julian   +9 more
core   +2 more sources

A Review of Tafamidis for the Treatment of Transthyretin-Related Amyloidosis [PDF]

, 2015
Transthyretin (TTR)-related amyloidosis (ATTR) is a devastating disease which affects a combination of organs including the heart and the peripheral nerves, and which has a fatal outcome if not treated within a average of 10 years.
Benson, Merril D., Waddington Cruz, Márcia   +1 more
core   +1 more source

Semi-Quantitative Models for Identifying Potent and Selective Transthyretin Amyloidogenesis Inhibitors [PDF]

, 2017
Rate-limiting dissociation of the tetrameric protein transthyretin (TTR), followed by monomer misfolding and misassembly, appears to cause degenerative diseases in humans known as the transthyretin amyloidoses, based on human genetic, biochemical and ...
Choi, Sungwook, Connelly, Stephen, Johnson, Steven M., Kelly, Jeffery W., Mortenson, David E., Powers, Evan T., Wilson, Ian A.   +6 more
core   +2 more sources